

Developing a Vaccine for Rheumatic Fever and Rheumatic Heart Disease: Current Research Strategies and Challenges

Msi Tipu Chowdhury¹, Harisul Hoque¹, Sm Mustafa Zaman¹, Manzoor Mahmood¹

¹Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Bangladesh.

Abstract

Rheumatic heart disease (RHD) is the most serious manifestations of rheumatic fever, which is caused by group A Streptococcus (GAS or Streptococcus pyogenes) infection. RHD is an auto immune sequelae of GAS pharyngitis, rather than the direct bacterial infection of the heart, which leads to chronic heart valve damage. Although antibiotics like penicillin are effective against GAS infection, improper medical care such as poor patient compliance, overcrowding, poverty, and repeated exposure to GAS, leads to acute rheumatic fever and RHD. Thus, effort to design a vaccine based on emm gene identification of GAS, M-protein going on for more than 40 years, is unlikely to succeed. M-protein is strain specific. Infection with one strain does not provide immunity from infection with another strain. Based on the emm gene identification, of 250 or more identified strains of GAS, the distribution is heterogenous and keeps changing. The M-protein gene sequence of the organism tends to mutate. A vaccine prepared from available strains may not be effective against a strain following mutation.

Keywords: Group A Streptococcus (GAS), Rheumatic Heart Disease (RHD), Vaccine.

Corresponding Author: Dr. MSI Tipu Chowdhury, Resident, Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

Received: December 2018

Accepted: December 2018

Introduction

It is generally accepted that rheumatic fever (RF) follows group A beta hemolytic streptococcal (GAS) infection. Since GAS infection spreads through droplets, overcrowding causes an increased transmission from person to person. Undernutrition or malnutrition can increase the susceptibility to infection. Poor socio-economic status results in an inability to obtain optimal medical care. Hence a higher prevalence in developing countries is predominantly related to low socioeconomic status.

The resurgence of RF in the Utah area in USA occurred in middle class families with a healthy lifestyle without overcrowding, a suburban population with facilities for good medical care indicates that improvement in socio-economic status alone cannot control RF.^[1] Virulence of RF is related to its capacity to cause more or less permanent cardiac damage. In Utah epidemic, carditis based on clinical combined with echocardiogram findings, occurred in almost 90 percent patients.^[1] Hence prevention of rheumatic heart disease requires preventing RF.

Prevention of RF can be considered under two approaches-primary prevention and secondary prevention.^[2]

➤ Secondary prevention

Secondary prevention consists in giving injections of intramuscular benzathine penicillin every three to four weeks depending on age and muscle mass to patients who have

suffered from acute RF to prevent recurrences and Secondary prophylaxis is ethically mandatory. However, secondary prophylaxis cannot reduce the burden of disease. If given properly, it reduces overall heart damage from subsequent attacks.

➤ Primary prevention

Primary prophylaxis consists in identifying that the patient has a sore throat, that it is GAS infection and giving penicillin to eradicate the GAS infection. Primary prophylaxis has too many loopholes and is almost impossible to practice even for individual patients.

Sore throat is a frequent trigger of antibiotic use, both in children and adults. While only a fraction of sore throats are related to GAS pharyngitis, the justification for antibiotic prescription is, in the great majority of cases, related to the perceived need to prevent GAS-related complications.^[3]

Primary prophylaxis is possible if an anti-GAS vaccine becomes available. Although a number of components of GAS organism are being studied in order to make a vaccine.

A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important WHO activity, influencing prioritization of investments. Here, the role, status and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision-making, availability and use. GAS vaccines should be considered for global prevention of the

range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. WHO developed a vision for vaccine development, highlighting strategic targets, product preferences and priority research and development activities.^[4]

Vaccine Development for RHD

Development of a vaccine for RHD started in the early 1960s with crude cell wall to purified M proteins⁵. In general, selection of vaccine candidates for any pathogen is Based on few characteristics such as;

- sub-cellular localization of the target protein,
- ability to induce immune responses,
- no molecular mimicry between target and host tissue proteins,
- conservation of target protein among all the available genomes of the species, and
- possibility of cloning the target protein (e.g., proteins with no or one trans membrane helix) [Figure 1].^[6-11]




Figure 1: Common characteristics of a potential vaccine candidate.

To be a vaccine candidate, other than virulence factors, proteins with an essential role in the pathogenesis or survival can also be used as a vaccine target. Vaccine targets for *Streptococcus pyogenes* can be classified into three major types:^[12]

- Vaccines based on cell surface proteins.
- Vaccines based on secreted proteins.
- Vaccines based on carbohydrates.

Adhesion proteins which help in the pathogen colonization could be used for vaccine design, since the antibodies produced against this protein will prevent colonization of pathogen on the host and further progression of the disease in the host tissue.^[13] In order to develop a vaccine, surface and secreted proteins are considered to be the suitable vaccine candidates in eliciting the antibody response, but when compared to the cytosolic proteins of *S. pyogenes*, they fail to meet some of the essential characteristics that are required for development of vaccine. For instance, limited coverage of some vaccine candidates (serum opacity factor and R28) can provide protection against only a certain number of serotypes while other antigens (group A carbohydrate) are not effective in eliciting high concentrations of antibodies,^[14,15] which are required to be used as a vaccine target.^[14,16] Hence, it is necessary to identify a novel vaccine candidate, which is highly immunogenic and also capable of

giving protection against wide spectrum of M serotypes.

Vaccines Based on Cell Surface Proteins

There are several cell surface protein like M protein, C5a peptidase (SCPA), C5a peptidase (SCPA), *S. pyogenes* cell envelope protein (SpyCEP), R28, *Streptococcus protective antigen* (Spa), *Streptococcal immunoglobulin binding protein* (Sib35).^[12]

M protein

Among the cell surface proteins, M protein of *S. pyogenes* has been studied extensively. Especially, the hyper variable amino terminal and the highly-conserved carboxyl regions have long been the target for vaccine development against RHD due to its immunogenicity and no cross-reactivity properties.^[17] However, the main limitation of using hyper variable N-terminal of M protein is the strain-specific immunity, thus multivalent vaccines have been developed by combining hyper variable N-terminal regions from different GAS serotypes.

Recently, Dale and colleagues¹⁸ constructed a new 30-valent M protein-based vaccine. This vaccine construct consists of N-terminal fragments (first 50 residues) of M protein from 30 different M serotypes that are predominant in North America and Europe and further they have shown to be immunogenic in rabbits. Interestingly, they have further found that this multivalent vaccine is protective against another 24 non-vaccine M serotypes, which are not included in the 30 valent vaccine construct.^[18] The reason for this cross-protection may be due to the amino acid sequence similarity present in the N-termini or high sequence similarity across the whole M protein found within the same emm-cluster.^[19]

Although some studies suggested that the level of bactericidal antibodies produced by C-terminal region of M protein may not be adequate to give complete protection against GAS infection²⁰, vaccine candidates such as *StreptIncor* and J,^[14] peptide which are derived from the C-terminal of M protein shown to be protective in animal models against RHD.^[21]

Vaccine Pipeline

Only two candidate vaccines are actively under evaluation in human trials. A phase I clinical trial of the MJ8VAX vaccine candidate developed by the Queensland Institute of Medical Research, Australia, were recently reported. The vaccine antigen is a 29-amino acid long peptide (J8) from the conserved carboxyl terminus region of the M protein,^[22] conjugated with diphtheria toxoid and adsorbed onto aluminium hydroxide. More investigations are planned to further optimise immunogenicity. The 30-valent *StreptAnova*, developed at the University of Tennessee, USA and Dalhousie University, Canada, is a M protein-based vaccine with 4 recombinant subunits, each containing seven or eight N-terminal fragments of 30 different emm types linked in tandem.^[23] The N-terminal fragment of the Spa antigen is also included in the construct.^[18]

The peptides were selected from acute and invasive isolates most prevalent in North America and Europe. A phase I clinical trial of the vaccine adjuvanted with alum was recently completed. This program builds on favourable

safety and immunogenicity evaluation of previous related constructs including a lower number of emm-type sequences.^[23] In preclinical development, the StreptIncor vaccine candidate construct developed by the University of São Paulo, Brazil, is based on the conserved region of the M5 protein, which comprises a 55-amino acid polypeptide containing conserved B- and T-cell epitopes. A phase I/IIa clinical trial of the vaccine candidate antigen formulated with alum is expected to start in 2018/2019.^[24] Investments in GAS vaccine R&D by major vaccine manufacturers have been limited. One candidate based on the conserved antigens streptolysin O, SpyAD, SpyCEP and group A carbohydrate conjugated with a carrier protein is being developed by GSK.^[25] The antigens selected are highly conserved and prevalent, either surface exposed or secreted, expressed during human infection, soluble and immunogenic in animals. Altogether, the scarcity of products in development as presented above underscore the need to expand and diversify the vaccine pipeline.

Safety Considerations

Safety concerns have constituted an important impediment to past vaccine development efforts. In 1969, the occurrence of ARF following streptococcal vaccination in 3 out of 21 volunteers vaccinated with a partially purified M3 protein was reported.^[26] This raised concerns about the safety of GAS vaccines and a theoretical risk of autoimmunity. In 1979, the United States Food and Drug Administration (FDA) prohibited the use of GAS organisms and its derivatives in any bacterial vaccine.^[27] However, the validity of such concerns raised by this single study were subsequently questioned. All three children had documented GAS infection before the onset of ARF, and all were siblings of ARF patients. They were exposed to very high and repeated dosing of a crude M-protein vaccine formulation. These factors may have influenced their risk of developing ARF. The FDA resolution was revoked in 2006, when the agency recognized the previous understanding as “both obsolete and a perceived impediment to the development of a GAS vaccine”.^[27] There had not been a GAS vaccine trial reported during a period of 25 years. Vaccine research resumed, with no similar adverse safety signal identified. Nonetheless, the field would benefit from consensus building on safety risk management strategies appropriately adapted to vaccine development status. Studies have often used serum auto-immunity panel screening, tissue cross-reactive immunofluorescence antibody assays and echocardiography to monitor for potential auto-immune events occurring post vaccination.^[23] While due diligence is needed, there is a strong perception that auto-antibody panels and echocardiographic monitoring are poor screening tools and of limited value as adequate safety monitoring requires sufficient endpoint sensitivity and specificity, especially when the number of trial participants is limited, as in early vaccine development. In clinical practice these tests are seldom used in isolation, as their contribution to diagnosis is strongly driven by pre-test probability determined by the clinical context. Borderline results and non-specific findings make interpretation difficult.^[28] Screening panels and echocardiographic evaluation may best be reserved for screening out subjects at increased risk of abnormalities

detected before entering into investigational vaccine studies.

Conclusion

Recent 30-valent vaccines based on M protein, which are shown to be protective against RHD in the US and European population¹⁸, are undergoing clinical trials. A global vaccine that covers other regions of the world, especially low-income countries, would be extremely helpful to eradicate RHD completely. With the recent computational advancements in the field of vaccinology²⁹, we hope that a protective vaccine against RHD is within reach, either through identification of novel antigens or through structure-based design of known antigens of GAS.

References

1. Veasy LG. Lessons learned from the resurgence of rheumatic fever in the United States. In: Narula J, Virmani R, Reddy KS, Tandon R, eds. Rheumatic Fever. Washington DC: Amer Registr of Path AFIP; 1999:69e78
2. Tandon R, Preventing rheumatic fever : M- protein based vaccine, Indian Heart Journal 2014; 66: 64-67
3. WHO-Group A Streptococcus Vaccine Development Technology Roadmap, 2018.
4. (<https://apps.who.int/iris/bitstream/handle/10665/279392/WHO-IVB-18.08-eng.pdf>)
5. Vekemans J, Gouvea-Reis F, Kim JH, Excler JL, SmeestersPR, O'Brien KL, “The path to group A Streptococcus vaccines, 2018 WHO research and development technology roadmap and preferred product characteristics, Infectious Diseases Society of America 2019.
6. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511.)
7. He Y, Xiang Z, Mobley HL. Vaxign: The first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol. 2010;2010297505.
8. Vivona S, Gardy JL, Ramachandran S, Brinkman FS, Raghava GP, Flower DR, et al. Computer-aided biotechnology: From immunoinformatics to reverse vaccinology. Trends Biotechnol. 2008;26(4):190_200.
9. Sette A, Rappuoli R. Reverse vaccinology: Developing vaccines in the era of genomics. Immunity. 2010;33(4):530–41.
10. Vivona S, Bernante F, Filippini F. NERVE: New enhanced reverse vaccinology environment. BMC Biotechnol. 2006;635.
11. Muzzi A, Masignani V, Rappuoli R. The pan-genome: Towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov Today . 2007;12(11-12):429-39.
12. Donati C, Rappuoli R. Reverse vaccinology in the 21st century: Improvements over the original design. Ann N Y Acad Sci. 2013;1285:115-32.
13. Gandhi GD, Krishnamoorthy N, Motal UMA, Yacoub M. Towards developing a vaccine for rheumatic heart disease, Global Cardiology Science and Practice 2017;4 <http://dx.doi.org/10.21542/gcsp.2017.4/dx.doi.org/10.21542/gcsp.2017.4>
14. Delany I, Rappuoli R, Seib KL. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med. 2013;3(5):a012476.
15. Courtney HS, Hasty DL, Dale JB. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun. 2003;71(9):5097-103.
16. Stalhammar-Carlemalm M, Areschoug T, Larsson C, Lindahl G. The R28 protein of Streptococcus pyogenes is related to several group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells. Mol Microbiol. 1999;33(1):208-19.
17. Huang YS, Fisher M, Nasrawi Z, Eichenbaum Z. Defense from the Group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor. J Infect Dis. 2011;203(11):1595-601i GD, Krishnamoorthy NMota

18. Pandey M, Batzloff MR, Good MF. Vaccination against rheumatic heart disease: A review of current research strategies and challenges. *Curr Infect Dis Rep.* 2012;14(4):381-90.
19. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. *Vaccine.* 2011;29(46):8175-8.
20. Sanderson-Smith M, Oliveira DM, Guglielmini J, McMillan DJ, Vu T, Holien JK, et al. A systematic and functional classification of *Streptococcus pyogenes* that serves as a new tool for molecular typing and vaccine development. *J Infect Dis.* 2014.
21. Courtney HS, Hasty DL, Dale JB. Serum opacity factor (SOF) of *Streptococcus pyogenes* evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. *Infect Immun.* 2003;71(9):5097-103.
22. Postol E, Alencar R, Higa FT, Freschi de Barros S, Demarchi LM, Kalil J, et al. StrepInCor: A candidate vaccine epitope against *S. pyogenes* infections induces protection in outbred mice. *PLOS One.* 2013;8(4):e60969.
23. Sekuloski S, Batzloff MR, Griffin P, et al. Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. *PLoS One* 2018;13:e0198658
24. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-Valent M Protein-Based Vaccine Evokes Cross-Opsonic Antibodies Against Non-Vaccine Serotypes of Group A Streptococci. *Vaccine* 2011 ; 29: 8175-8.
25. Guilherme L, Ferreira FM, Köhler KF, Postol E, Kalil J. A Vaccine against *Streptococcus pyogenes*. *Am J Cardiovasc Drugs,* 2013 ; 13: 1-4.
26. Bensi G, Mora M, Tuscano G, et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A *Streptococcus* case. *Mol Cell Proteomics,* 2012 ; 11: M111.015693.
27. Massell BF, Honikman LH, Amezcua J. Rheumatic Fever Following Streptococcal Vaccination. Report of three cases. *JAMA,* 1969 ; 207: 1115-9.
28. Centre for Disease Control. 21 CFR 610.19 - Status of specific products; Group A streptococcus. Code of Federal Regulations. Available at: <https://www.federalregister.gov/documents/2005/12/02/05-23546/revocation-of-status-of-specific-products-group-a-streptococcus>. Accessed 05 September 2018.
29. Schödel F, Moreland NJ, Wittes JT, et al. Clinical development strategy for a candidate group A streptococcal vaccine. *Vaccine* 2017; 35: 2007-14.
30. Flower DR, Perrie Y. Immunomic discovery of adjuvants and candidate subunit vaccines. New York: Springer; 2013.

Copyright: © the author(s), publisher. Academia Journal of Medicine is an Official Publication of “Society for Health Care & Research Development”. It is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Chowdhury MT, Hoque H, Zaman SM, Mahmood M. Developing a Vaccine for Rheumatic Fever and Rheumatic Heart Disease: Current Research Strategies and Challenges. *Acad. J Med.* 2018;1(2):16-19.

DOI: [dx.doi.org/10.21276/ajm.2018.1.2.5](https://doi.org/10.21276/ajm.2018.1.2.5)

Source of Support: Nil, **Conflict of Interest:** None declared.